• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lenalidomide - Key patent, SPC, and data exclusivity expiry (7 country coverage) Product Image

Lenalidomide - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • Published: June 2013
  • GenericsWeb

FEATURED COMPANIES

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Lenalidomide
Lenalidomide indications: Transfusion-dependent anaemia due to low or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities; Multiple myeloma in combination with Dexamethasone
Lenalidomide innovator: Celgene (Revlimid)

Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis READ MORE >

Celgene (Revlimid)

Format Properties
Electronic (Online Access) The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos